Cargando…

Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy

Inflammation and oxidative stress are critical underlying mechanisms associated with COVID-19 that contribute to the complications and clinical deterioration of patients. Additionally, COVID-19 has the potential to alter the composition of patients’ gut microbiota, characterized by a decreased abund...

Descripción completa

Detalles Bibliográficos
Autores principales: Martín Giménez, Virna Margarita, Modrego, Javier, Gómez-Garre, Dulcenombre, Manucha, Walter, de las Heras, Natalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419057/
https://www.ncbi.nlm.nih.gov/pubmed/37569625
http://dx.doi.org/10.3390/ijms241512249
_version_ 1785088419055009792
author Martín Giménez, Virna Margarita
Modrego, Javier
Gómez-Garre, Dulcenombre
Manucha, Walter
de las Heras, Natalia
author_facet Martín Giménez, Virna Margarita
Modrego, Javier
Gómez-Garre, Dulcenombre
Manucha, Walter
de las Heras, Natalia
author_sort Martín Giménez, Virna Margarita
collection PubMed
description Inflammation and oxidative stress are critical underlying mechanisms associated with COVID-19 that contribute to the complications and clinical deterioration of patients. Additionally, COVID-19 has the potential to alter the composition of patients’ gut microbiota, characterized by a decreased abundance of bacteria with probiotic effects. Interestingly, certain strains of these bacteria produce metabolites that can target the S protein of other coronaviruses, thereby preventing their transmission and harmful effects. At the same time, the presence of gut dysbiosis can exacerbate inflammation and oxidative stress, creating a vicious cycle that perpetuates the disease. Furthermore, it is widely recognized that the gut microbiota can metabolize various foods and drugs, producing by-products that may have either beneficial or detrimental effects. In this regard, a decrease in short-chain fatty acid (SCFA), such as acetate, propionate, and butyrate, can influence the overall inflammatory and oxidative state, affecting the prevention, treatment, or worsening of COVID-19. This review aims to explore the current evidence regarding gut dysbiosis in patients with COVID-19, its association with inflammation and oxidative stress, the molecular mechanisms involved, and the potential of gut microbiota modulation in preventing and treating SARS-CoV-2 infection. Given that gut microbiota has demonstrated high adaptability, exploring ways and strategies to maintain good intestinal health, as well as an appropriate diversity and composition of the gut microbiome, becomes crucial in the battle against COVID-19.
format Online
Article
Text
id pubmed-10419057
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104190572023-08-12 Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy Martín Giménez, Virna Margarita Modrego, Javier Gómez-Garre, Dulcenombre Manucha, Walter de las Heras, Natalia Int J Mol Sci Review Inflammation and oxidative stress are critical underlying mechanisms associated with COVID-19 that contribute to the complications and clinical deterioration of patients. Additionally, COVID-19 has the potential to alter the composition of patients’ gut microbiota, characterized by a decreased abundance of bacteria with probiotic effects. Interestingly, certain strains of these bacteria produce metabolites that can target the S protein of other coronaviruses, thereby preventing their transmission and harmful effects. At the same time, the presence of gut dysbiosis can exacerbate inflammation and oxidative stress, creating a vicious cycle that perpetuates the disease. Furthermore, it is widely recognized that the gut microbiota can metabolize various foods and drugs, producing by-products that may have either beneficial or detrimental effects. In this regard, a decrease in short-chain fatty acid (SCFA), such as acetate, propionate, and butyrate, can influence the overall inflammatory and oxidative state, affecting the prevention, treatment, or worsening of COVID-19. This review aims to explore the current evidence regarding gut dysbiosis in patients with COVID-19, its association with inflammation and oxidative stress, the molecular mechanisms involved, and the potential of gut microbiota modulation in preventing and treating SARS-CoV-2 infection. Given that gut microbiota has demonstrated high adaptability, exploring ways and strategies to maintain good intestinal health, as well as an appropriate diversity and composition of the gut microbiome, becomes crucial in the battle against COVID-19. MDPI 2023-07-31 /pmc/articles/PMC10419057/ /pubmed/37569625 http://dx.doi.org/10.3390/ijms241512249 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Martín Giménez, Virna Margarita
Modrego, Javier
Gómez-Garre, Dulcenombre
Manucha, Walter
de las Heras, Natalia
Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy
title Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy
title_full Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy
title_fullStr Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy
title_full_unstemmed Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy
title_short Gut Microbiota Dysbiosis in COVID-19: Modulation and Approaches for Prevention and Therapy
title_sort gut microbiota dysbiosis in covid-19: modulation and approaches for prevention and therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10419057/
https://www.ncbi.nlm.nih.gov/pubmed/37569625
http://dx.doi.org/10.3390/ijms241512249
work_keys_str_mv AT martingimenezvirnamargarita gutmicrobiotadysbiosisincovid19modulationandapproachesforpreventionandtherapy
AT modregojavier gutmicrobiotadysbiosisincovid19modulationandapproachesforpreventionandtherapy
AT gomezgarredulcenombre gutmicrobiotadysbiosisincovid19modulationandapproachesforpreventionandtherapy
AT manuchawalter gutmicrobiotadysbiosisincovid19modulationandapproachesforpreventionandtherapy
AT delasherasnatalia gutmicrobiotadysbiosisincovid19modulationandapproachesforpreventionandtherapy